Navigation Links
Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
Date:3/24/2011

THE WOODLANDS, Texas, March 24, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Pablo Lapuerta, M.D. has joined the company as its chief medical officer, responsible for directing clinical development of Lexicon's drug candidates from Phase 2 proof-of-concept through Phase 3 and approval.  Dr. Lapuerta has 15 years of pharmaceutical industry experience in a variety of leadership roles in drug development, global medical affairs and outcomes research strategy across multiple therapeutic areas, including cardiovascular disease, endocrinology, gastroenterology, and neurology.  Most recently, Dr. Lapuerta served as vice president at Bristol-Myers Squibb where he was responsible for global development of an Alzheimer's disease drug candidate with the associated use of an innovative biomarker.

(Photo:  http://photos.prnewswire.com/prnh/20110324/DA71095)

"Dr. Lapuerta's extensive experience in clinical development, regulatory strategy, and medical affairs are especially valuable as we progress the four programs we currently have in mid-stage clinical studies," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "His breadth of knowledge in multiple therapeutic areas meshes well with Lexicon's broad pipeline in drug discovery and development."

Dr. Lapuerta obtained his undergraduate degree from Harvard College and his medical degree from Harvard Medical School. He completed his training in internal medicine at the University of North Carolina at Chapel Hill followed by a post-doctoral research fellowship at the University of California at Los Angeles in neuroscience. He served as assistant p
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... IRVINE, Calif. , July 30, 2015 /PRNewswire/ ... Novartis /Alcon executives have recently contacted the Company ... will begin as early as Monday, August 3, ... been quoted as saying that the coming electronic ... billions of dollars over the next several years.  ...
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the second quarter ending June 30, 2015. ... the organization.  We are excited to be near the ... ever conducted with topline results expected in the fourth ... PTC Therapeutics, Inc. "Translarna is now commercially available in ...
(Date:7/30/2015)...  Growth of the U.S. nonprescription market is primarily ... users to the OTC market. Due to an increasingly ... switch activity over the next five years with several ... brands entering the market into existing categories. ... (even those with low to moderate likelihood), the market ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... June 16 New independent microbiology testing reveals that one in every ... positive for one of three types of pathogens that spread easily and endanger ... , , ... that causes sickness and even death in people with lowered immune systems, were ...
... BRADENTON, Fla. , June 16 Xacore ... Ellis Services and Solutions Enterprises, LLC (ESSE) headed by retired ... his group of experienced professionals to tackle the challenge of ... protection DSP radio headset technology with the strengths of ESSE,s ...
Cached Medicine Technology:Consumers at Risk: One in Six Wood Pallets in Los Angeles Discovered With Potentially Deadly Pathogens 2Consumers at Risk: One in Six Wood Pallets in Los Angeles Discovered With Potentially Deadly Pathogens 3Consumers at Risk: One in Six Wood Pallets in Los Angeles Discovered With Potentially Deadly Pathogens 4Xacore Partners With ESSE, Headed by Retired Army Four Star General, to Tackle Military Hearing Loss 2Xacore Partners With ESSE, Headed by Retired Army Four Star General, to Tackle Military Hearing Loss 3
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Girl Scouts ... out bullying across Georgia through the Girl Scout "Be a Friend First" program. Representatives ... Thursday, July 30. , “Peach State Health Plan and our parent company, Centene ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... The Mount ... on research projects that evaluate the potential of related, experimental treatments. The collaboration moves ... of Health to award Columbia Care one of five state licenses to produce and ...
(Date:7/31/2015)... ... July 31, 2015 , ... BioViva USA, Inc. (“BioViva”), a to-clinic ... aging diseases. , BioViva announces it has begun a fundraiser through Maximum Life ... (AD) and find a cure. MaxLife will grant 100% of the money raised to ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... the Northern District of Ohio, Western Division (Case No. 3:15-cv-00397) involving the ... the women experienced spontaneous migration of their Implanon® implants, inability to locate the ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Heart Fit Clinic has increased a patient's ... heart rate of 150 beats versus 100 beats, this is a big deal," says ... give life back to patients with heart disease," he adds. People with angina are ...
Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2
... measures, study finds , FRIDAY, Aug. 7 (HealthDay News) -- ... cancer have surgery to remove their breasts or ovaries in ... report. , Their study included 211 women, aged 35 to ... to increase the risk of breast and ovarian cancer. The ...
... , , WEST JORDAN, Utah, Aug. ... Jewish Community Center (JCC) the fourth annual Dannon Next Generation Nutrition Grant ... Lake County community. The JCC received $30,000 in support of its ... Fun, Fit & Healthy! will offer weekly, nutritionist-developed ...
... /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: ... Chairman and Chief Executive Officer, will present at the upcoming ... will take place on Wednesday, August 12, 2009 at 11:00 ... About Transition, ----------------, , ...
... , , , , ... selected Artefill, the first and only FDA-approved microsphere-enhanced collagen filler for ... wrinkles. Kathleen Stegman, RN, M.A. has been an avid Artefill user ... for the long lasting correction of wrinkles. , , ...
... LAUDERDALE, Fla., Aug. 7 Averaging ... critical 24/7 patient information call center, Hospice Partners On Call ... secure colocation facility, to safeguard its powerful server infrastructure and ... Partners On Call decided to move their back-up servers to ...
... , DENVER, Aug. 7 An innovative program ... disease patients and teams of pharmacists, nurses, primary care doctors, and ... two years after they left the program by keeping them in ... by Kaiser Permanente published in The American Journal of Managed Care ...
Cached Medicine News:Health News:Many Opt for Surgery to Lower Breast, Ovarian Cancer Risk 2Health News:The Dannon Company Awards The I.J. & Jeanne Wagner Jewish Community Center the Fourth Annual Dannon Next Generation Nutrition Grant 2Health News:The Dannon Company Awards The I.J. & Jeanne Wagner Jewish Community Center the Fourth Annual Dannon Next Generation Nutrition Grant 3Health News:The Dannon Company Awards The I.J. & Jeanne Wagner Jewish Community Center the Fourth Annual Dannon Next Generation Nutrition Grant 4Health News:Transition Therapeutics to Present at Canaccord Adams 29th Annual Global Growth Conference 2Health News:Midwest Medical Aesthetics Helps Defy Nature and Wrinkles with Artefill 2Health News:Midwest Medical Aesthetics Helps Defy Nature and Wrinkles with Artefill 3Health News:Hospice Partners On Call Selects Category 5 Hurricane Rated 1Vault Networks to Safeguard Server and Call Center Infrastructure 2Health News:Electronic Health Records Help Cardiac Patients Remain Healthy 2Health News:Electronic Health Records Help Cardiac Patients Remain Healthy 3Health News:Electronic Health Records Help Cardiac Patients Remain Healthy 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: